Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 13 December 2025
2019-11-11 09:36:00 Monday ET

Apple upstream semiconductor chipmaker TSMC boosts capital expenditures to $15 billion with almost 10% revenue growth by December 2019. Due to high global d
2018-11-25 12:37:00 Sunday ET

The Chinese administration delivers a written response to U.S. demands for trade reforms. This strategic move helps trigger more formal negotiations between
2023-12-09 08:28:00 Saturday ET

International trade, immigration, and elite-mass conflict The elite model portrays public policy as a reflection of the interests and values of elites. I
2019-11-23 08:33:00 Saturday ET

MIT financial economist Simon Johnson rethinks capitalism with better key market incentives. Johnson refers to the recent Business Roundtable CEO statement
2024-04-30 09:30:00 Tuesday ET

With clean and green energy resources and electric vehicles, the global auto industry now navigates at a newer and faster pace. Both BYD and Tesla have
2020-09-17 12:28:00 Thursday ET

Many successful business organizations develop their distinctive capabilities and unique value propositions for strategic reasons. Paul Leinwand and Cesa